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The human immunodeficiency virus type 1 (HIV-1) surface envelope glycoprotein (Env) complex, a homotrimer containing gp120 surface
glycoprotein and gp41 transmembrane glycoprotein subunits, mediates the binding and fusion of the virus with susceptible target cells. The Env
complex is the target for neutralizing antibodies (NAbs) and is the basis for vaccines intended to induce NAbs. Early generation vaccines based on
monomeric gp120 subunits did not confer protection from infection; one alternative approach is therefore to make and evaluate soluble forms of
the trimeric Env complex. We have directly compared the immunogenicity in rabbits of two forms of soluble trimeric Env and monomeric gp120
based on the sequence of HIV-1JR-FL. Both protein-only and DNA-prime, protein-boost immunization formats were evaluated, DNA-priming
having little or no influence on the outcome. One form of trimeric Env was made by disrupting the gp120–gp41 cleavage site by mutagenesis
(gp140UNC), the other contains an intramolecular disulfide bond to stabilize the cleaved gp120 and gp41 moieties (SOSIP.R6 gp140). Among the
three immunogens, SOSIP.R6 gp140 most frequently elicited neutralizing antibodies against the homologous, neutralization-resistant strain, HIV-
1JR-FL. All three proteins induced NAbs against more sensitive strains, but the breadth of activity against heterologous primary isolates was
limited. When antibodies able to neutralize HIV-1JR-FL were detected, antigen depletion studies showed they were not directed at the V3 region but
were targeted at other, undefined gp120 and also non-gp120 epitopes.
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The development of an effective vaccine to prevent the spread
of human immunodeficiency virus type 1 (HIV-1) is a global
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potent and broadly reactive neutralizing antibody (NAb) res-
ponse will be a critical constituent of any vaccine-elicited
protective immune response against HIV-1. NAbs are targeted
to, and raised by, the viral envelope glycoproteins (Env) encoded
by the env gene. During synthesis of the Env precursor (gp160),
the protein is trimerized in the endoplasmic reticulum (ER) via
non-covalent interactions between gp41 subunits (Earl et al.,
1991). Cellular endoproteases of the furin family then cleave
gp160 into gp120–gp41 complexes in a post-ER compartment
(probably the trans-Golgi network) (Moulard and Decroly,
2000). The functional Env complex is a homotrimer containing
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(TM) glycoproteins are non-covalently associated. This fully
matured Env complex is incorporated into virions, where it
serves to mediate receptor binding and the subsequent
conformational changes that drive the fusion of the viral and
cell membranes (Berger et al., 1999; Gallo et al., 2003; Poignard
et al., 2001; Wyatt and Sodroski, 1998).
Recombinant monomeric gp120 subunits have been tested
extensively as immunogens, but they have succeeded only in
eliciting antibodies capable of recognizing the immunizing
antigen and of neutralizing atypically sensitive HIV-1 strains,
including ones adapted to replication in vitro (Parren et al.,
1999). When tested in efficacy trials, the monomeric gp120
vaccines were found to be ineffective (Flynn et al., 2005;
Gilbert et al., 2005; Graham andMascola, 2005). Because of the
importance placed upon the induction of an effective NAb
response, designing and testing more sophisticated forms of
Env-based immunogens is one of the foci of current HIV-1
vaccine research. One approach involves making soluble
recombinant proteins that better mimic the form of the native,
trimeric Env complex present on the virion surface (Burton et
al., 2004). Usually, such proteins are made by truncating the
full-length gp160 protein immediately prior to the gp41
transmembrane domain, a procedure that allows a soluble
gp140 protein to be secreted and purified. Mutations introduced
to disrupt the endoproteolytic cleavage site between gp120 and
gp41 fortuitously stabilize the interactions between the gp41
ectodomains (gp41ECTO) sufficiently to allow purification of
trimeric Env proteins (gp140UNC) (Center et al., 2004;
Chakrabarti et al., 2002; Srivastava et al., 2002; Yang et al.,
2000, 2002; Zhang et al., 2001). Additional trimer-stabilizing
modifications can be added to these gp140UNC proteins (Center
et al., 2004; Chen et al., 2004; Srivastava et al., 2003; Yang et
al., 2000, 2002; Zhang et al., 2001). When tested in small
animal models, some gp140UNC proteins are moderately
superior to monomeric gp120 proteins for induction of NAbs
(Barnett et al., 2001; Bower et al., 2004; Kim et al., 2005;
VanCott et al., 1997; Yang et al., 2001).
As an alternative approach, we have engineered a disulfide
bond to stabilize the interaction between the gp120 and
gp41ECTO subunits; this modification enables the SOS gp140
protein to be cleaved without the rapid dissociation of gp120
from gp41ECTO (Binley et al., 2000; Schulke et al., 2002). In its
full-length form, the SOS form of Env is fusion-competent
provided the disulfide bond is reduced after receptor binding
has occurred (Abrahamyan et al., 2003; Binley et al., 2003). An
additional substitution (I559P) introduced into gp41ECTO
strengthens gp41–gp41 interactions, allowing the purification
of soluble trimers known as SOSIP gp140 proteins (Sanders et
al., 2002). Replacement of the natural sequence of the cleavage
site between gp120 and gp41 with an hexa-Arg (R6) motif
increases the efficiency of cleavage (Binley et al., 2002). In a
recent study, NAbs against some primary HIV-1 Env-pseudo-
typed viruses were induced in a subset of rabbits immunized
with SOSIP gp140 trimers (Beddows et al., 2005).
Cleaved and uncleaved forms of gp140 trimers do differ in
their structure, as judged by MAb-reactivity profiles (Herrera etal., 2005; Pancera andWyatt, 2005; Schulke et al., 2002; Si et al.,
2003). However, it has been unclear whether one form is
superior to the other as an immunogen. Here, we describe a
formal comparison of the immunogenicity of SOSIP gp140
trimers with uncleaved gp140 trimers and monomeric gp120
using a DNA-prime, protein-boost immunization format. In
sensitive assays based on Env-pseudotyped viruses, antibodies
raised to SOSIP gp140 were more frequently active against
HIV-1JR-FL than antibodies to monomeric gp120 or gp140UNC
proteins. However, the breadth of the NAb response to all three
immunogens was quite limited. In a sub-study, we compared
responses to purified SOSIP gp140 and gp120 proteins admi-
nistered without DNA priming, the results suggesting that,
overall, DNA-priming prior to protein immunization had little
impact on the generation of NAbs. Our conclusion is that JR-FL
SOSIP gp140 trimers were superior to gp140UNC and gp120
proteins in this study, albeit to a modest extent. Additional
development work will be required if SOSIP gp140 proteins are
to become practical vaccines.
Results
Design, expression and immunization of monomeric and
trimeric Env immunogens
We recently described a study in which we compared diffe-
rent ways to present Env glycoproteins in the DNA priming
(soluble vs. membrane-bound Env) and soluble protein boost
(soluble, cleaved trimeric SOSIP.R6 gp140 Env vs. bead-
immobilized trimeric Env) phases of an immunization regimen
in rabbits (Beddows et al., 2005). Here, we have built on that
study by now directly comparing the immunogenicity of mono-
meric gp120, trimeric SOSIP.R6 gp140 and a trimeric, cleavage-
defective form of Env (gp140UNC), all based on the HIV-1JR-FL
Env sequence.
The design, expression and characterization of the soluble,
cleaved, trimeric SOSIP.R6 gp140 Env protein has been des-
cribed elsewhere (Beddows et al., 2005; Binley et al., 2000,
2002; Sanders et al., 2002; Schulke et al., 2002). Membrane-
bound and soluble forms of cleavage-defective Env (gp140UNC)
were both made by replacing the sequence of the wild-type (Wt)
cleavage sequence, REKR (Dubay et al., 1995), with a non-
scissile IEGR motif (Schulke et al., 2002). The soluble, trimeric
form of gp140UNC was purified from transfection supernatant
using lectin affinity and size exclusion chromatography (SEC)
columns (Schulke et al., 2002).
We conducted a prolonged series of immunizations involving
priming the rabbits twice with DNA expressing a membrane-
bound form of Env, followed by 4 boosts with soluble proteins.
The study involved five Arms, each containing 4 rabbits
(Fig. 1A). In Arms F, G and H, the animals were primed twice
during a 4-week period with DNA expressing membrane-bound
proteins Wt gp140 (i.e., gp140 that is potentially cleavable but
probably substantially uncleaved), gp140UNC (i.e., the cleavage-
defective IEGR mutant) and SOSIP.R6 gp140 (i.e., gp140
intended to be cleaved as efficiently as possible), respectively.
Membrane-bound forms of Env (i.e., gp140 cytoplasmic-tail
Fig. 1. Design of the immunizations and the induction of anti-gp120 binding
antibodies. (A) The schematic for the immunization study highlights the
membrane-bound DNA construct (gp140 Wt, gp140UNC or SOSIP.R6 gp140)
used for priming (open arrows), the type and timing of each of the protein
immunizations (filled arrows) and the serum collection times (grey arrows).
(B) Generation of anti-gp120 antibodies in the study. Rabbits were primed (filled
symbols) or not (open symbols) with 1 mg of pPPI4 expressing either codon-
optimized membrane-bound gp140 Wt Env (square), gp140UNC (circle) or
SOSIP.R6 gp140 (triangle) at the times indicated. The anti-gp120 antibody
responses weremeasured by ELISA. Each datum point represents the mean (n=4
animals) midpoint anti-gp120 binding titer for each immunization group (Arms
F, G, H, I and M).
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initial study indicated they were superior to soluble proteins for
this purpose (Beddows et al., 2005). The protein boosts in Arms
F, G and H were the corresponding soluble gp120 or gp140
proteins (30 μg) given over a 44-week period, initially using
QS-21 adjuvant, later Ribi adjuvant (see below). No DNA
priming was carried out in Arms I and M; these arms directly
compared the immunogenicities of soluble SOSIP.R6 gp140
trimers (Arm I) and gp120 monomers (Arm M) (Fig. 1). The
animals were bled at the indicated times and their sera were
tested for anti-Env binding and neutralizing antibody responses.
Anti-gp120 binding antibody responses
Midpoint gp120 bindingAb titers were determined by ELISA
for each animal at each time point and are presented as the mean
values for the 4 rabbits in each Arm (Fig. 1B). Immediately after
the two DNA immunizations, the mean anti-gp120 binding titers
in sera from the animals immunized with gp120 (Arm F,4.7×104), gp140UNC (Arm G, 4.0×10
4) and SOSIP.R6 gp140
(Arm H, 2.8×104) were similar. The titers then declined
gradually by approximately 10-fold but were elevated by
∼100-fold by the first protein boost (week 14 bleed). Additional
transient increases occurred in response to subsequent boosts,
but the maximum response never went beyond the peak titer
established at week 14. Overall, the anti-gp120 binding titers in
Arms F–H were always similar at all time-points (±3-fold),
although the titers in the SOSIP.R6 immunized animals (Arm H)
were usually a little lower than in the animals given gp120 or
gp140UNC, as observed previously (Beddows et al., 2005).
The midpoint anti-gp120 binding titers in sera from animals
immunized with Env proteins without DNA priming (Arms I
and M) varied over time in a similar manner to those in the
DNA-primed rabbits. Thus, the peak titers were generated early
(weeks 6 and 14 for SOSIP.R6 gp140 or gp120 immunized
animals, respectively) and were not enhanced by subsequent
immunizations.
Of note is that the adjuvant used for the Env protein boosts
was switched from the dose-sparing, saponin-derived adjuvant
QS-21 to a monophosphoryl lipid A-based adjuvant (Ribi) at
week 28. Our previous immunization study suggested that while
anti-Env binding titers were not affected by such an adjuvant
switch, this strategy might have a modest, beneficial effect on
overall neutralization titers (Beddows et al., 2005). In the
present study, the change of adjuvant again made no difference
to the overall anti-gp120 binding titers (Fig. 1B).
There was no significant difference between the anti-gp120
binding antibody titers in animals immunized with SOSIP.R6
(with or without DNA prime) and in those immunized with
either gp120 or gp140UNC at either week 22 (p=0.36; Mann–
Whitney, one tail) or week 44 (p=0.42).
Neutralization of Env-pseudotyped HIV-1
To assess functional antibody responses, we first measured
neutralizing activity against HIV-1 pseudotype viruses expres-
sing the JR-FL or MN Env proteins, using U87.CD4 cells
bearing the appropriate coreceptor (Beddows et al., 2005).
JR-FL Env is derived from the CCR5-using (R5) primary isolate
HIV-1JR-FL which is moderately neutralization resistant and
represents the autologous strain for the immunization studies,
while MNEnv is derived from a highly passaged, CXCR4-using
(X4), neutralization sensitive strain, HIV-1MN. We previously
used these Env-pseudotyped viruses to monitor the generation of
a baseline level of neutralizing activity (HIV-1MN) and to
identify sera containing NAbs active against more resistant
primary isolates (HIV-1JR-FL) (Beddows et al., 2005).
Neutralization of Env-pseudotyped HIV-1MN was determined
for every serum sample available from each animal. Data derived
from selected time points are shown in Table 1. The test sera were
obtained following the second DNA and the four protein
immunizations for the DNA-primed groups (Arms F, G and H),
and following the second, third, fourth, fifth and sixth protein
immunizations for the protein-only groups (Arms I and M).
DNA priming (week 6) was able to induce NAbs against Env-
pseudotyped HIV-1MN, but only to the 50% endpoint and at
Table 1
Neutralization of Env-pseudotyped HIV-1 by gp120-, gp140UNC- and SOSIP.R6-immunized rabbits
Arm DNA Protein Animal Neutralization of Env-pseudotyped HIV-1 MN and JR-FL by rabbit sera a
Week 6 Week 14 Week 22 Week 30
MN JR-FL MN JR-FL MN JR-FL MN JR-FL
F Wt gp120 840 27 ND >160 – 153 – >160 –
841 21 ND >160 – >160 – >160 –
842 40 ND >160 – >160 16 >160 –
843 95 ND >160 – 98 – >160 –
G UNC UNC Trimer 844 16 ND 116 – 143 – >160 –
856 – ND >160 – >160 – >160 –
846 17 ND 40 – 88 17 144 –
847 – ND – – 60 13 117 –
H SOSIP.R6 SOSIP.R6 Trimer 848 16 ND >160 – 123 14 >160 –
849 18 ND 151 – 105 19 >160 63
850 – ND >160 – 93 17 154 –
851 27 ND >160 – >160 19 >160 –
I None SOSIP.R6 Trimer 852 >160 45 >160 19 >160 18 133 –
853 >160 17 >160 104 >160 102 106 33
854 57 – >160 – >160 – 83 –
855 130 – 98 – >160 – 95 –
M None gp120 1188 – – >160 – >160 – 124 –
1189 14 – 148 – >160 – 88 –
1190 – – 98 16 140 17 39 –
1191 >160 – >160 – >160 – >160 –
a The reciprocal of the dilution that resulted in 50% neutralization of Env-pseudotyped HIV-1 on coreceptor-bearing U87.CD4 cells (mean of two experiments). A
dash indicates that <50% neutralization was observed at the 1:10 dilution. ND, not done.
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tionswith soluble Env proteins, such that neutralization at the 90%
endpoint was routinely observed (data not shown). The maximum
90% titers against HIV-1MNwere attained after one (week 14), two
(week 22) or three (week 30) protein immunizations (Arms F, G
and H) (data not shown). For the animals given only soluble Env
protein (Arms I and M), 90% neutralization of HIV-1MN was
maximal after the second (week 6), third (week 14) or fourth
(week 22) immunization. HIV-1MN neutralization titers (90%
endpoint) were not significantly different when the rabbits
immunized with gp120 (Arm F, week 30 and Arm M, week 14)
and SOSIP.R6 gp140 (ArmH, week 30 and Arm I, week 14) were
compared (Mann–Whitney U test), irrespective of whether the
animals had been primedwithDNA before receiving three protein
immunizations (data not shown). This pattern of response is
broadly consistent with whatwe observed previously (Beddows et
al., 2005).
NAbs against the autologous, but more resistant HIV-1JR-FL
strain were generated more slowly and their appearance could
not be predicted from inspection of the anti-gp120 binding or
HIV-1MN neutralization titers (Table 1). In addition, the titers
against HIV-1JR-FL were lower and were only detectable in a
subset of animals. Among the DNA-primed animals (Arms F, G
and H), only those immunized with SOSIP.R6 gp140 had a
consistent neutralization response against HIV-1JR-FL. The 50%
neutralization titer was >10 for sera from all 4 animals in Arm H
at week 22. However, only animal #849 generated what we
consider to be a significant and sustained neutralizing antibodyresponse to HIV-1JR-FL (50% titer >40). Two of the four animals
immunized with SOSIP.R6 gp140 protein only (#852 and #853)
generated NAbs against HIV-1JR-FL, one of them (#853) to the
90% endpoint (Table 1 and data not shown). In contrast, sera
from animals immunized with gp120 or gp140UNC neutralized
HIV-1JR-FL more weakly and transiently (Table 1). Neutraliza-
tion of the control MLV Env-pseudotyped virus was not seen,
indicating that non-specific inhibitory or toxic factors were not
present in the test sera (data not shown).
In contrast to our previous study (Beddows et al., 2005), we
found that switching from the adjuvant QS-21 to Ribi from
week 28 made no difference to the generation of NAbs in any of
the study Arms.
Independent assessment of neutralization activity
The neutralization data described above are consistent with
our previous observations that some rabbits immunized with
SOSIP.R6 gp140, but not those receiving gp120, can generate
antibodies able to neutralize HIV-1JR-FL (Beddows et al., 2005).
As an independent test of our findings and to determine whether
the SOSIP gp140 immunogens could elicit cross-reactive
neutralizing antibodies against heterologous HIV-1 strains,
selected sera were also tested in the PhenoSense™ HIV Entry
Assay (Richman et al., 2003). The test panel comprised 9 HIV-1
Env-pseudotyped viruses derived from sexually transmitted,
clonal, geographically diverse, R5 primary isolates that are
representative of a broad range of neutralization phenotypes.
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(Arms F, G and H), or at week 14 (Arms I and M), from all four
rabbits in each Arm were tested. The neutralizing activities of
sera from animals in Arms F, G and H at week 44 were not
significantly different from the activities of the corresponding
week 30 sera. Hence, for brevity, only the data from week 30 are
presented in Table 2. None of the pre-immune sera contained
neutralizing activity (<50% inhibition at 1:25 dilution) (data not
shown). Regardless of the method of immunization (DNA
prime, protein boost or protein only immunizations) or the Env
protein used (gp120 monomer, gp140UNC trimer or SOSIP.R6
gp140 trimer), all the immunogens induced antibodies that
neutralized the atypically sensitive strains, HIV-1SF162 and HIV-
1NL4/3, to high titers (Table 2). However, only sera from animals
immunized with SOSIP.R6 gp140 protein with (#849) or
without (#852 and #853) DNA-priming had any neutralizing
activity against HIV-1JR-FL. These animals are the same three
whose sera could also neutralize HIV-1JR-FL in our in house
neutralization assay.
Neutralization curves generated against HIV-1NL4/3, HIV-
1JR-FL and the murine leukemia virus (MLV) Env-pseudotyped
virus control, for one animal immunized with gp120 (#842) and
for one given SOSIP.R6 gp140 (#849), are highlighted in Fig. 2.
At a 1:10 dilution, the SOSIP.R6 gp140 serum neutralized the
HIV-1JR-FL pseudovirus by 100%, the HIV-1NL4/3 pseudovirusTable 2
Assessment of cross-neutralizing activity in the PhenoSense HIV entry assay
Arm DNA Protein Week Animal Neutralization of Env-
SF162 NL4/3 JR-
F Wt gp120 30 840 424 101 –
841 289 81 –
842 582 152 –
843 786 31 –
G UNC UNC Trimer 30 844 1227 110 –
856 461 79 –
846 776 43 –
847 97 72 –
H SOSIP.R6 SOSIP.R6 Trimer 30 848 80 66 –
849 271 89 25
850 839 103 –
851 1050 478 –
I None SOSIP.R6 Trimer 14 852 975 146 4
853 330 60 15
854 919 64 –
855 191 62 –
M None gp120 14 1188 237 192 –
1189 128 67 –
1190 109 124 –
1191 168 69 –
Reference HIV-1+ plasma N16 Mean 3945 1071 6
SD 244 166
a The reciprocal of the dilution which resulted in 50% neutralization of Env-pseudo
neutralization was observed at the 1:25 dilution. Plasma (N16) was from an HIV-1-i
assay variation (n=9 tests). MLV, murine leukemia virus Env-pseudotype; NA, notby 85% but the MLV pseudovirus by <50%. The gp120 serum
neutralized the HIV-1NL4/3 pseudovirus by 80% at 1:10 dilution
but failed to neutralize either the HIV-1JR-FL or the MLV
pseudoviruses (<50%). The pattern of progressively increasing
neutralization with decreasing serum dilution suggests the
infectivity reduction is a specific process. Few of the test sera
were able to cross-neutralize the 6 other Env subtype B HIV-1
strains in the panel, although 3 of 8 sera from animals given
SOSIP.R6 gp140 and 2 of 4 sera from gp140UNC-immunized
animals had some activity against HIV-1BaL, compared to 0 of 8
for the gp120-immunized animals. The reference HIV-1 positive
plasma, N16, was broadly active against the test strains. None of
the rabbit sera neutralized the control MLV Env-pseudotyped
virus, indicating that non-specific inhibitory or toxic factors
were not present in the test sera (Table 2).
Qualitative assessment of HIV-1 neutralization responses
The neutralization of HIV-1JR-FL by sera from some of the
rabbits immunized with SOSIP.R6 gp140 trimers in both the
in-house Env-pseudotyped virus neutralization assay and the
PhenoSense™ HIV Entry Assay, and the limited cross-reac-
tivity of these sera against other primary viruses, are findings
consistent with our earlier study (Beddows et al., 2005).
To try to understand why the autologous virus waspseudotyped HIV-1 or MLV by rabbit sera a
FL BaL QH0692 JR-CSF US93073 92HT593 QH0115 MLV
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
28 – – – – – –
– – – – – – –
25 – – – – – –
– – – – – – –
– – – – – – –
7 – 25 – – – – –
– – – – – – –
42 – – – – – –
4 32 – – – – – –
6 – – – – – – –
30 – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
– – – – – – –
0 282 66 190 54 79 – –
4 117 7 11 5 43 NA NA
typed HIV-1 on coreceptor-bearing U87.CD4 cells. A dash indicates that <50%
nfected individual and was used as a reference standard to control for assay-to-
applicable.
Fig. 2. Neutralization of JR-FL by SOSIP.R6 gp140 but not gp120 immunized
animals. A week 30 serum sample from an animal immunized with gp140 Wt
DNA/gp120 protein (Arm F, #842, open symbol) was compared with a serum
sample from an animal immunizedwith SOSIP.R6 gp140DNA/SOSIP.R6 gp140
(Arm H, #849, closed symbol) in the PhenoSense™ HIV Entry Assay.
Neutralization curves are shown for each serum against (A) HIV-1JR-FL,
(B) HIV-1NL4/3 and (C) murine leukemia virus (MLV) Env-pseudotyped
viruses.
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analyzed the antibody specificities present in the most potent
serum samples.
To do so, we first purified the immunoglobulin (Ig) fractions
from serum samples from two animals primed with DNA then
boosted with Env protein (Arm F, #841; ArmH, #849), and from
two immunized with protein only (Arm I, #853; ArmM, #1191).
Animals #841 and #1191 had received gp120, the other two
(#849 and #853) were immunized with SOSIP.R6 gp140.
Comparing the unfractionated sera and the purified Ig showed
the neutralizing activity against HIV-1JR-FL and HIV-1MN was
Ig-mediated (Table 3). It was not due therefore to chemokinesor other serum factors that could interfere with infection of the
target cells and give a false indication of the presence of NAbs
in the test sera.
We next wished to determine whether neutralization of
HIV-1JR-FL was caused by antibodies directed to gp120 and,
within gp120, to the V3 region. To do this, we incubated selected
sera with bead-immobilized BSA (negative control), gp120JR-FL
or a cyclic V3JR-FL peptide (Beddows et al., 2005). To validate
the depletion procedure, we tested whether the bead-immobi-
lized protein or peptide could remove the anti-V3JR-FLMAb PA1
or the anti-gp120MAb b12, after these MAbs were spiked into a
pool of pre-immune rabbit sera (Figs. 3A and 3B). Both the
gp120- and the V3 peptide-beads depleted the PA1 MAb from
the test serum by >99%, and the gp120-beads removed a similar
proportion of the added b12 MAb. As expected, the V3 peptide-
beads did not remove any of the b12MAb, and neitherMAbwas
depleted by the control BSA-beads.
When sera from selected gp120 (#841 and #1188)- and
SOSIP.R6 gp140 (#849 and #853)-immunized rabbits were
similarly treated, the gp120-beads lowered the anti-gp120
binding antibody titers by 50-fold (98.3±0.9% depletion) in
each case (Fig. 3C). The depletion procedure was therefore
capable of removing most of the antigen-induced anti-gp120
antibodies from the sera. Only a minor fraction of the total anti-
gp120 antibodies in the sera was directed towards the V3 region
of gp120 because the V3 peptide-beads had little effect on the
overall anti-gp120 titers (Fig. 3C).
The untreated serum and the BSA-, V3 peptide- and gp120-
depleted serum fractions were then tested for neutralizing
activity against HIV-1JR-FL and HIV-1MN Env-pseudotyped
viruses (Table 4). As expected, the sera from the gp120-
immunized rabbits (#841 and #1188) were unable to neutralize
HIV-1JR-FL, either before or after the bead-depletion procedure.
The HIV-1JR-FL neutralizing activity of sera from the SOSIP.R6
gp140-immunized rabbits (#849 and #853) was slightly reduced
(∼25%) by incubation with the V3 peptide-beads but was
substantially, yet incompletely, reduced (∼60%) by the gp120-
beads. Neutralization of HIV-1MN was only slightly lowered by
treatment of the sera with the V3 peptide-beads but almost
completely eliminated by the gp120-beads (Table 4). This
observation is consistent with the conclusion that V3 antibodies
constitute only a minor fraction of the total anti-gp120
antibodies present in the sera overall (Fig. 3C).
Although the anti-gp120 binding (Fig. 3C) and HIV-1MN
neutralizing activities (Table 4) were substantially (∼99% and
∼90%, respectively) depleted when the sera from SOSIP.R6
gp140-immunized rabbits were incubated with the gp120-beads,
this procedure reduced the HIV-1JR-FL neutralizing activities
(Table 4) of sera from animals #849 and #853 by only 53% and
64%, respectively. For comparison, two sera from a previous
study (Beddows et al., 2005) were also included in this experi-
ment; the depletion profiles obtained were similar to those
obtained before (Table 4).
To start to define the neutralizing antibody specificities pre-
sent within the more active rabbit sera, we investigated whether
NAbs directed towards the V1/V2 loops of gp120 or the mem-
brane-proximal external region (MPER) of gp41 had been
Table 3
Neutralization of JR-FL and MN Env-pseudotyped HIV-1 by rabbit immune sera is mediated by Ig
Arm DNA Protein Animal Neutralization of Env-pseudotyped HIV-1 by serum or Ig a
JR-FL MN
Serum Ig Serum Ig
50% 90% 50% 90% 50% 90% 50% 90%
F Wt gp120 841 – – – – >160 25 112 17
H SOSIP.R6 SOSIP.R6 Trimer 849 81 16 99 15 >160 41 148 29
I None SOSIP.R6 Trimer 853 53 12 38 – 125 32 144 19
M None gp120 1191 – – – – >160 27 >160 15
a The reciprocal of the dilution of sera or Ig preparation which resulted in 50% or 90% neutralization of Env-pseudotyped HIV-1 on coreceptor-bearing U87.CD4
cells (representative of two independent experiments). A dash indicates that <50% neutralization was observed at the 1:10 dilution. Sera was taken from bleeds
collected at week 14 (Arms I and M) or 30 (Arms F and H).
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gp120-immunized animals (#841 and #1188) and SOSIP gp140-
immunized animals (#849 and #853) were tested. In peptide
competition assays, neither a V1 peptide nor a V2 peptide was
able to reduce the neutralizing activity of any of these sera
against either of the HIV-1JR-FL and the HIV-1MN Env-
pseudotyped viruses; adding both peptides together was also
without effect (Fig. 4A, and data not shown). For an assessment
of neutralizing activity against the gp41 MPER, we used
chimeric SIVmac239 viruses expressing the MPER-located
epitopes for the human NAbs 2F5 and 4E10 (Yuste et al., 2004).
Neither the chimeric viruses SIV239-2F5 and SIV239-4E10 nor
the parental SIVmac239 virus were neutralized by any of the
sera tested (Fig. 4B and data not shown). Taken together, these
studies suggest that little or no neutralizing antibody activity in
these rabbit sera was directed against the V1/V2 region of gp120
or the MPER region of gp41.
Discussion
We previously reported on the immunogenicity of a cleaved,
disulfide-stabilized trimeric gp140 (SOSIP.R6) protein derived
from the primary virus-like, neutralization-resistant strain, HIV-
1JR-FL (Beddows et al., 2005). In this follow-up study, we have
directly compared the immunogenicity of monomeric gp120,
cleavage-defective trimeric gp140 (gp140UNC) and SOSIP.R6
gp140 proteins, all based on HIV-1JR-FL.
As previously, we compared the immune responses in rabbits
that received Env trimers or gp120 monomers, with or without
prior priming with a mammalian expression vector encoding the
homologous codon-optimized env DNA administered through
an in vivo electroporation procedure (Mathiesen, 1999; Widera
et al., 2000). In contrast to our earlier study (Beddows et al.,
2005), the DNA priming procedure did not improve the overall
gp120 binding or HIV-1JR-FL Env-pseudotyped virus neutrali-
zation titers, though it did again increase the numbers of animals
responding, at least initially. In a recent study of a DNA prime,
protein boost protocol intended to explore the immunogenicity
of gp120 proteins from multiple genetic subtypes, the sensitive
strains MN, SF162 and NL4/3 were neutralized in thePhenoSense™ HIV Entry Assay at titers significantly higher
than those we describe here. However, as in our own study, the
more resistant strains were neutralized only sporadically (Wang
et al., 2006). The reasons why the two protocols yielded
different outcomes in respect of the neutralization-sensitive
viruses are presently under investigation.
All twelve rabbits in the DNA-prime, protein-boost Arms
and all eight rabbits in the protein only immunization Arms
generated antibodies capable of neutralizing HIV-1MN to >90%.
HIV-1MN neutralization titers usually peaked following three
protein immunizations (week 30 for Arms F, G and H; week 14
for Arms I and M). Overall, there was no significant difference
in neutralization of HIV-1MN by sera from animals immunized
with SOSIP.R6 and from ones that were not.
Following two DNA and two protein immunizations (week
22), all four SOSIP.R6 gp140 immunized animals produced
antibodies capable of neutralizing HIV-1JR-FL by >50% in our
in-house Env-pseudotype assay, albeit to low titer. In compar-
ison, sera from one and two of the four animals, respectively,
that were immunized with monomeric gp120 or gp140UNC
under similar conditions, could neutralize HIV-1JR-FL by >50%.
In contrast to animals immunized with gp120 or gp140UNC, two
of the SOSIP.R6 gp140-immunized animals, one receiving a
DNA-prime (Arm H, #849), one given protein-only (Arm I,
#853), generated NAb responses against HIV-1JR-FL that were
both strong and sustained.
Sera from all animals were independently tested, under
contract, using the PhenoSense™ HIV Entry Assay. This assay
confirmed that neutralizing antibodies against HIV-1JR-FL had
been induced in three of the eight animals immunized with
SOSIP.R6 gp140 (#849, #852, #853; Table 2). The two sera
most strongly active against HIV-1JR-FL in our in-house Env-
pseudotype assay (#849 and #853) were also the most effective
against the same virus in the PhenoSense™ HIV Entry Assay.
Sera from none of the animals immunized with gp120 or
gp140UNC proteins neutralized HIV-1JR-FL in the PhenoSense™
HIV Entry Assay. In the latter assay, neutralization of the hyper-
sensitive strains HIV-1NL4/3 and HIV-1SF162 was more con-
sistently achieved, and at high titer, but these responses were
seen irrespective of the nature of the immunogen. In contrast,
Fig. 3. Depletion of gp120 binding antibodies by gp120 and V3 peptides. CNBr-
Sepharose beads with coupled BSA (filled triangles), cyclic V3JR-FL peptide
(open circles) or gp120JR-FL (open diamonds) were used to deplete a rabbit pre-
immune serum pool spiked with (A) the V3-specific MAb PA1, or (B) the anti-
gp120 MAb b12, before testing in a gp120 ELISA. The non-depleted serum was
also assayed (filled squares). (C) Sera from rabbits in the DNA-primed Arms F
(#841; filled bars) and H (#849; grey bars), and the non-primed groups I (#853;
hatched bars) and M (#1188; open bars) were left untreated (‘Unt’) or depleted
using BSA-, V3- or gp120-coupled beads before determination of midpoint
binding titers against gp120. The data shown are representative of the results of
2–3 individual experiments.
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in the test panel, although three sera from SOSIP.R6 gp140-
immunized animals and two sera from rabbits given gp140UNC
did weakly neutralize HIV-1BaL. Overall, the outcome of the
study is qualitatively similar to our earlier one using SOSIP.R6
gp140 (Beddows et al., 2005).
Various depletion experiments showed that anti-gp120
antibodies were almost entirely responsible for neutralization
of HIV-1MN by the test sera, with little contribution from anti-
V3 antibodies. In addition, peptide-competition assays suggest
that little or no neutralizing activity against HIV-1JR-FL or
HIV-1MN could be attributed to antibodies directed against the
V1/V2 region of gp120. In contrast, V1-directed antibodies did
contribute significantly to the neutralizing activity of sera
generated by immunizing guinea pigs with trimeric YU-2 gp140
proteins (Li et al., 2006). The reasons for the differences betweenthis outcome and ours could lie with the Env proteins used, the
adjuvants or the test animals. We did observe that a significant
fraction of the neutralizing response to HIV-1JR-FL in our test
sera was attributable to antibodies that were not depleted from
the sera by incubation with monomeric gp120. This neutralizing
activity could reflect the presence of antibodies against gp120
epitopes that are not well exposed on monomeric gp120 (for
example, CD4-induced epitopes), of antibodies to conforma-
tional epitopes that are not present on the monomeric form of
gp120 (for example, trimer-specific epitopes or gp120 epitopes
affected by the presence of gp41), or of antibodies directed at
epitopes that are simply not present on any form of gp120 (for
example, gp41 epitopes). Of note, of course, is that the SOSIP.
R6 gp140 immunogen does contain the gp41 ectodomain. How-
ever, we used SIVmac239 chimeric viruses to perform a
preliminary investigation of whether neutralizing antibodies
directed against the MPER region of gp41 were present (i.e.,
antibodies with properties similar to human MAbs 2F5 and
4E10) (Yuste et al., 2004). We found no evidence for the pre-
sence of such antibodies in the sera we tested. Additional studies
of antibody specificity, isotype and avidity will be important to
gain a better understanding of how sera from Env-immunized
animals does, occasionally, neutralize representative primary
viruses at respectable titers (Bower et al., 2006; Burton et al.,
2004).
Although we have been able to generate antibodies with
activity against the homologous strain using the SOSIP.R6
gp140 protein, at least two significant obstacles remain to be
overcome. Firstly, the induction of such antibodies in rabbits is
variable; not every animal immunized in an identical manner
responds in the same way. This phenomenon has also been
reported by others (Grundner et al., 2004) and it may be
attributable to individual variation in the ability to induce
effective T-helper responses for B-cell maturation (Grundner et
al., 2004). Additional research on how best to present Env
trimers to the immune system, and how to induce T-helper
responses, may yield dividends. The second issue relates to the
difficulty in inducing cross-neutralizing responses to represen-
tative primary isolates both within and across the genetic
subtypes. Even within subtype B, our success rate was limited
in this and our previous study (Beddows et al., 2005). A lack of
breadth in the neutralizing antibody response is a common
observation in studies of the immune response to various
gp140UNC proteins (Barnett et al., 2001; Bower et al., 2004;
Kim et al., 2005; Yang et al., 2001). Overcoming this significant
obstacle may depend on the outcome of further rounds of
protein engineering guided by additional information on the
structure of the native Env trimer and its sites for the binding of
neutralizing antibodies (Burton et al., 2004).
Materials and methods
Design, expression and purification of Env proteins and
plasmids used for immunizations
All plasmids and Env glycoproteins were derived from the
genetic background of HIV-1JR-FL a subtype B, R5 primary
Table 4
Neutralization of Env-pseudotyped HIV-1 following depletion on BSA, V3 peptide or gp120-conjugated beads
Arm DNA Protein Animal Neutralization of Env-pseudotyped HIV-1 by rabbit antisera a
JR-FL MN
Untreated BSA V3 gp120 Untreated BSA V3 gp120
F Wt gp120 841 – – – – 144 (23) 145 (29) 120 (46) 31 (33)
H SOSIP.R6 SOSIP.R6 Trimer 849 104 (26) 93 (21) 78 (16) 49 (10) 158 (5) 150 (21) 141 (36) 20 (7)
I None SOSIP.R6 Trimer 853 42 (11) 36 (2) 33 (3) 15 (5) 144 (24) >160 (NA) 81 (70) 11 (3)
M None gp120 1188 – – – – >160 (NA) >160 (NA) 106 (58) 18 (8)
SOS.R6 SOSIP.R6 Trimer 241 88 98 67 12 128 103 37 –
Wt gp120 5695-3 – – – – 134 146 63 21
a Dilution of rabbit antisera before (untreated) or after depletion on BSA, cyclic V3 peptide or gp120-coupled cyanogen bromide–Sepharose beads which resulted in
50% neutralization of Env-pseudotyped HIV-1 on coreceptor-bearing U87.CD4 cells. Values represent the mean of three to four independent experiments (SD in
parentheses) for animals 841, 849, 853 and 1188 or the mean of two experiments for 241 and 5695-3 (sera taken from previous study; Beddows et al., 2005). A dash
indicates that <50% neutralization was observed at the 1:10 dilution. NA, not applicable as all values >160.
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from the high level mammalian expression vector, pPPI4, using
codon-optimized genes, as described previously (Binley et al.,
2000, 2002; Sanders et al., 2002; Schulke et al., 2002). The
gp140UNC construct was made by introducing two amino acid
substitutions (R508I/K510G) into the natural Env cleavage site
(Dubay et al., 1995), by site-directed mutagenesis (Stratagene,
La Jolla, CA). This alteration, from REKR to IEGR, prevents
proteolytic cleavage by cellular endoproteases (Schulke et al.,
2002). The sequence integrity of all clones was confirmed prior
to use. The expression and purification of the Env constructs
used in this study have been described in detail (Beddows et al.,
2005).
Immunization protocol
The care, maintenance and immunization of rabbits were
carried out by Aldevron LLC (Fargo, ND) under contract, as
previously described (Beddows et al., 2005; Mathiesen, 1999;
Widera et al., 2000). The rabbits were DNA-immunized using
an electroporation procedure at weeks 0 and 4, followed by
boosting immunizations with 30 μg of a JR-FL Env protein,
formulated in QS-21 adjuvant (Antigenics Inc., New York, NY)
(Fig. 1A, Arms F, G and H). For the ‘protein only’ immu-
nization regimens (Arms I andM), rabbits were immunized with
30 μg of the indicated Env protein at weeks 0 and 4, followed by
further protein immunizations at the same times as the DNA-
primed animals. Thus, all the rabbits received the same total
number of immunizations, administered at the same times,
differing only in the mode of application for the first two
immunizations (DNA vs. protein). From week 28, instead of
QS-21, the various Env proteinswere formulated inRibi adjuvant.
For immunization, Env proteins were administered by injection
intomultiple anatomical sites (50μl intradermal at six sites, 200μl
intramuscular, in each hind leg and 300 μl subcutaneous in the
neck region; a total of 1 ml), as described elsewhere (VanCott
et al., 1997). The timing of each bleed and dose and the
constructs used for each study animal are outlined in Fig. 1A.ELISA for antibody binding to monomeric gp120
The binding of rabbit serum antibodies or MAbs to
monomeric gp120 immobilized on plastic via the C-terminal
antibody D7324 was measured by enzyme-linked immunosor-
bent assay (ELISA) using the appropriate anti-species alkaline
phosphatase conjugate and the AMPAK colorimetric detection
system (Dako Diagnostics), as previously described (Moore et
al., 1996; Moore and Sodroski, 1996). Midpoint binding titers
were estimated by interpolation.
HIV-1 neutralization assays
Env genes expressing full-length gp160 proteins were
derived from the HIV-1 isolates JR-FL (obtained from Dr. T.
Dragic, Albert Einstein College of Medicine, New York) and
MN (Beddows et al., 2005). The generation of Env-pseudo-
typed virus stocks and the use of the engineered HIV-1
coreceptor bearing cell lines U87.CD4.CCR5 and U87.CD4.
CXCR4 for Env-pseudotyped virus infection and neutralization,
have been described previously (Beddows et al., 2005; Gordon
et al., 1999; Herrera et al., 2003).
The potential for peptides derived from the V1 (KDVNA-
TNTTNDSEGTMERGEIKN) or V2 (NITTSIRDEVQKE-
YALFYKLDVVPIDNNNT) regions of JR-FL to reduce the
neutralizing capacity of selected rabbit sera was assessed by
competitive inhibition. Neutralization assays were performed as
described above, but with minor modifications at the initial
virus-serum incubation stage. Thus, peptides (50 μg/ml) were
incubated with a 1:5 dilution of rabbit serum for 30 min at room
temperature followed by the addition of HIV-1JR-FL or HIV-1MN
Env-pseudotyped luciferase reporter viruses for 1 h at 37 °C.
The mixture was then transferred to wells containing the appro-
priate coreceptor bearing U87.CD4 cells.
The neutralization properties of selected pre- and post-
immune sera were also evaluated, under contract, by
Monogram Inc. (South San Francisco, CA). The automated
PhenoSense™ HIV Entry Assay measures the infectivity of
Fig. 4. Exploration of neutralizing antibody specificity to V1V2 and gp41 MPER epitopes. (A) Neutralization of HIV-1JR-FL (left panels) and HIV-1MN (right panels)
by selected post-immune rabbit sera in the presence or absence of exogenously added V1 and V2 peptides. Week 14 serum samples were tested from the subset of
rabbits that were immunized with either SOSIP.R6 trimer (#853; top panels) or gp120 (#1188; bottom panels), in the absence of DNA priming. (B) Neutralization of
SIVmac239 chimeric viruses expressing epitopes for the human NAbs 2F5 (239-2F5) and 4E10 (239-4E10). Pre-immune (filled symbols) and post-immune (open
symbols) rabbit sera were tested at the indicated dilutions. The tested samples were pre-immune and week 30 bleeds from rabbits immunized using a DNA-prime,
protein boost protocol (gp120, #841, diamond; SOSIP.R6 gp140, #849, triangle) or pre-immune and week 14 bleeds from rabbits immunized in a protein-only
procedure (gp120, #1188, square; SOSIP.R6 gp140, #853, circle). The data points represent the mean (±SD) percentage neutralization compared to control (no
antibody) and were derived from triplicate determinations within a single experiment.
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single-cycle assay using CCR5/CXCR4-expressing U87.CD4
cells (Binley et al., 2004; Richman et al., 2003).
The neutralizing antibody specificities of selected pre- and
post-immune sera were also evaluated against SIVmac239 virus
engineered to express the epitopes for HIV-1 NAbs 2F5 and
4E10, as described elsewhere (Yuste et al., 2004).
Immunoglobulin (Ig) purification
Total Ig was purified from final bleed rabbit sera using
Protein A Sepharose (1 ml column; GE Healthcare Bios-
ciences, Piscataway, NJ), according to the manufacturer's
instructions. Briefly, rabbit sera were diluted to a volume of
12 ml in phosphate-buffered saline (PBS) and added to the
column at a flow rate of 0.5 ml/min. The column was then
washed with twenty column volumes of buffer before elution
with 0.1 M glycine. The eluted fractions were immediately
neutralized with 1 M Tris (pH 9). The presence of Ig in thefractions was then assessed using reduced SDS gels. The
fractions containing Ig were pooled and desalted into PBS using
a PD-10 Desalting Column (GE Healthcare Biosciences).
Amicon Ultra Centrifugal Filters with a 30-kDa molecular
weight cutoff (Millipore, Billerica, MA) were then used to
concentrate the eluted material to ∼80% of the initial serum
volume. Ig concentrations were estimated using a Rabbit IgG
Assay Kit (Pierce, Inc., Rockford, IL) and anti-gp120 titers were
determined in an ELISA. The purified Ig samples were then
further adjusted with PBS to be comparable with the Ig
concentration in the unfractionated rabbit serum, to facilitate
direct comparisons between the serum and the purified Ig in
subsequent neutralization assays.
Antibody depletion from sera by gp120 or V3 peptides
Cyanogenbromide (CNBr)-activated Sepharose 4Bbeadswere
used to couple monomeric gp120JR-FL, cyclic V3JR-FL peptide Ac-
CTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHC-NH2) or
339S. Beddows et al. / Virology 360 (2007) 329–340BSA, according to the manufacturer's instructions (Amersham
Biosciences). The depletion of rabbit antibodies from immune
sera using these beads was performed as previously described
(Beddows et al., 2005).
Statistical analyses
Prism (Graphpad) was used for statistical analysis. The titers
did not consistently pass the D'Agostino-Pearson omnibus
normality test when pooled into groups according to the
immunization regimen. Differences were therefore analyzed
non-parametrically (Mann–Whitney test).
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